A study presented during the 2020 ASH Annual Meeting has suggested that certain driver mutations for myeloproliferative neoplasms (MPNs) can be traced back to when they were acquired as early as in utero.
If you can not only detect clones early but then calculate their rates of growth with a repeat sample you can then plot the growth trajectory of these clones and estimate the latency to a potential clinical manifestation, thus offering opportunities for early preventive strategies, said Jyoti Nangalia, MBBChir, senior study author, and cancer research UK clinician scientist at Sanger Institute, in a virtual presentation of the data.
The study comprised a cohort of 10 patients with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), with a median age of 48.5 (range, 20-76).
Each patients peripheral blood and bone marrow samples were grown into single cellderived hematopoietic colonies. Each colony underwent whole-genome sequencing. A total of 952 whole-genome sequences were produced, each reflecting that of the single cell from which the colony was derived.
Right from the start of life, as our cells are dividing, mutations are being acquired, and theyre being passed down from generation to generation such that at any one time, the mutations within individual cells represent natural bar codes that can be used to trace back the ancestry of those cells right to the start of life, and so we did this in MPNs, said Nangalia.
Phylogenetic trees were drawn based on the somatic mutations that had been identified. Driver mutations were subsequently assigned to the tree and evaluated for appearance patterns across each colony, reflecting the relative development of the driver mutations in each patient.
Because the total number of somatic mutations in an individual colony was shown to correlate with age, investigators converted the relative development of mutations to absolute development to more accurately understand clonal evolution.
Our blood stem cells require mutations throughout life, roughly 18 mutations across the genome per year. Therefore, by applying patient-specific mutation rates and clone-specific mutation rates, we were able to put a start time and an end time to each individual branch across the phylogenetic trees in our cohort, said Nangalia.
In the first patient who had been diagnosed with ET at the age of 21, the JAK2 mutation was acquired early, timing between 6.2 weeks post-conception and 1.3 years of age. In the phylogenetic tree, the branching downstream of JAK2 demonstrated how the single stem cell that acquired JAK2 expanded into a clone of stem cells in rapid succession.
Similarly, in the second patient diagnosed with PV at the age of 31, the JAK2 mutation was acquired early, timing between 4.2 weeks post-conception and 8.6 years of age. Clonal expansion also demonstrated a DNMT3A mutation, which is the most common mutation in age-related clonal hematopoiesis, said Nangalia. However, in this patient, the mutation was also acquired early, timing between 4.6 weeks post-conception and 7.8 years of age, growing slowly before reaching a detectable clonal fraction.
In some patients, the JAK2 and DNMT3A mutations were acquired very early, including in utero. In one patient diagnosed with PV at age 33, the JAK2 mutation was acquired between 9.1 weeks post-conception and 4.1 months after birth, and the DNMT3A mutation was acquired between 19.4 weeks and 22.2 weeks post-conception. Another patient with PV showed that the DNMT3A mutation was acquired as early as between 1.2 weeks and 7.9 weeks post-conception.
In the patient with PV diagnosed at age 33, evidence of clonal evolution in the MPN clone was shown over 3 decades, cascading from a JAK2 mutation 4.1 months post-birth to homozygous JAK2 at 17.8 years to 1q amplification at 33 years.
In other patients, JAK2 was acquired as the second driver mutation in an already expanded DNMT3A-mutated clone.
Notably, a patient diagnosed with ET at age 54 had acquired DNMT3A R882H by 2 years of age, which is one of the most common mutations found in acute myeloid leukemia, said Nangalia. However, in another patient who had been diagnosed with ET at 76 years of age, there was a driverless clonal expansion.
We know that clonal hematopoiesis can often lack driver mutations and is thought to be the case in up to 50% of patients with clonal hematopoiesis. Here, we showed that that also has a single-cell origin. What is driving clonal expansion in this individual in that particular clone, we do not know, said Nangalia.
Across the cohort, recurrent or similar genetic aberrations were found in individual patients. A patient diagnosed with PV at age 53, who acquired a JAK2 exon 12 mutation in childhood, developed 3 independent DNMT3A mutations and 4 independent homozygous acquisitions stemming from their JAK2 exon 12 mutation.
Other patients demonstrated evidence of independent acquisitions of 1q amplifications, leading to myelofibrotic transformation. Another patient demonstrated evidence of multiple independent acquisitions of JAK2 V617F, suggesting that factors other than driver mutations, such as the patients germline or microenvironment within the bone marrow, also influence clonal evolution.
In the second portion of the study, investigators revisited the patients for whom phylogenetic trees had been drawn and re-sequenced the mutations that had been identified in the phylogenetic trees in the whole blood.
Combining the mutant clonal fractions in blood with the pattern of branching in the trees, investigators calculated the rate at which the clones had been growing over each patients lifespan.
Clone rates varied significantly. For example, in a patient with 3 mutant clones that had been acquired in uteroDNMT3A, JAK2, and JAK2/TET2the rates of annual growth were 9% (95% CI, 5%-25%), 67% (95% CI, 6%-246%), and 233% (95% CI, 143%-360%), respectively, the latter of which translates to a doubling-in-size time of every 7 months.
Regarding clones that had the same genetic makeup, such as clones consisting solely of the JAK2 V617F driver mutation, the annual growth rate varied among individual patients, ranging from 18% (95% CI, 13%-23%) to 68% (95% CI, 41%-95%).
This again suggests that there are factors other than JAK2 that determine the consequences of acquiring it in individual patients, said Nangalia.
Additional results revealed that the rate of growth was associated with the time of diagnosis. In patients with slow growth rates of less than 50%, over 50 years had gone by prior to diagnosis, whereas in patients with growth rates over 100%, it took less than 10 years before a diagnosis was made.
In retroactively calculating what the clonal fractions would have been leading up to diagnosis, the slow growing JAK2 clones could have been detected with sensitive assays 40 years prior to diagnosis and up to 10 years before diagnosis for faster growing clones.
Providing additional perspective during a press briefing, Robert Brodsky, MD, moderator, and director of the Division of Hematology at Johns Hopkin Medicine stated, These results suggest that there may be untapped opportunities to detect these conditions much earlier and potentially intervene and prevent disease development.
Williams N, Lee J, Moore L, et al. Driver mutation acquisition in utero and childhood followed by lifelong clonal evolution underlie myeloproliferative neoplasms. Presented at: 2020 ASH Annual Meeting & Exposition; December 5-8, 2020; virtual. Abstract LBA-1.
See the original post here:
MPN Driver Mutations Can Be Acquired as Early as in Utero, Study Shows - Targeted Oncology
- The Rise of Longevity Therapeutics - Pharmaceutical Executive - May 28th, 2021
- Tooth Regeneration Market Size | COVID-19 Impact Analysis | Forecast to 2027 investigated in the latest research - WhaTech - May 28th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Market Report 2021: In Total, At Least 68 Distinct Market Competitors Now Offer Various Types of iPSC... - April 18th, 2021
- Emergent drift of Dental Regenerative Products Market By the World in Upcoming Year 2021-2027 with Leading Key Players: Provia Laboratories, LLC,... - April 18th, 2021
- Worldwide Cell Therapy Industry to 2027 - Increasing Prevalence of Chronic Diseases is Driving the Market - PRNewswire - April 4th, 2021
- Outlook on the Cell Therapy Global Market to 2027 - by Therapy Type, Product, Technology, Application, End-user and Geography - GlobeNewswire - April 4th, 2021
- Exclusive Report on Global Gene Therapy Market Analysis Report 2021 and Forecast to 2029 with different segments, Key players KSU | The Sentinel... - April 4th, 2021
- Stem Cells- Definition, Properties, Types, Uses, Challenges - February 4th, 2021
- Experts Predict the Hottest Life Science Tech in 2021 and Beyond - The Scientist - February 2nd, 2021
- Bone Therapeutics, Rigenerand Ink Cell Therapy Deal - Contract Pharma - January 19th, 2021
- Bone Therapeutics and Rigenerand sign partnership for cell therapy process development - GlobeNewswire - January 19th, 2021
- Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing - Science Advances - December 10th, 2020
- Accumulated genetic variations: What they are and why they matter to a complete health picture - MedCity News - December 3rd, 2020
- The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019 -... - November 25th, 2020
- Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency - Health Europa - November 18th, 2020
- Cell Therapy Market Attractiveness, Competitive Landscape and Key Players MEDIPOST, Kolon TissueGene, NuVasive, Fibrocell Science - The Think... - November 18th, 2020
- Minaris invests to triple capacity in Europe - Bioprocess Insider - BioProcess Insider - November 9th, 2020
- Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader - November 9th, 2020
- Minaris Regenerative Medicine to Significantly Expand Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan - b3c newswire - November 3rd, 2020
- The Zinc Finger Nuclease Technology market to witness an incremental CAGR between 2020 and 2030 - Eurowire - November 3rd, 2020
- Technological Innovations and Pandemic Analysis Till 2030: Cell Therapy Manufacturing Market - Eurowire - October 28th, 2020
- Novel Strategies for Targeting the Guardian of the Genome Emerge - OncLive - October 23rd, 2020
- SFARI | New collaboration between SFARI and Nancy Lurie Marks Family Foundation will generate hundreds of iPSC lines for autism research - SFARI News - October 21st, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 21st, 2020
- A pathway to nowhere? A critique of the National Academy of Sciences report on genome editing - BioNews - October 13th, 2020
- Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni - Science Magazine - September 25th, 2020
- Strategic Analysis to Understand the Competitive Outlook of Cell Therapy Manufacturing Market - The News Brok - September 3rd, 2020
- Stem Cells Market Development Status, Emerging Technologies, Regional Trends and Comprehensive Research Study 2025 - The Daily Chronicle - August 28th, 2020
- Cell Therapy Manufacturing Market To Experience Significant Growth During The Forecast Period 2020-2029 - Scientect - August 28th, 2020
- Cell Therapy Manufacturing Market 2020 Report Including COVID-19 Impact Analysis and Forecast till 2029 - Scientect - August 22nd, 2020
- Cell Therapy Market Opportunities, Threats, Trends, Applications, And Growth Forecast To 2027 | MEDIPOST, Osiris Therapeutics, NuVasive, Cells for... - August 22nd, 2020
- Outlook on the Worldwide Hunter Syndrome Industry to 2030 - ResearchAndMarkets.com - Yahoo Finance - August 7th, 2020
- Edited Transcript of CLDX.OQ earnings conference call or presentation 6-Aug-20 8:30pm GMT - Yahoo Finance - August 7th, 2020
- Gene Therapy Market By Industry Type, By Brand And Major Players 2020-2027 - Market Research Posts - August 6th, 2020
- CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - August 4th, 2020
- Tooth Regeneration Market Size -Future of growth, Top Capital Facts, Global Industry Analysis, Share, Growth, Trends and Forecast 2020 - 2025 - Market... - July 29th, 2020
- Somatic Stem Cells | SpringerLink - July 29th, 2020
- -Catenin safeguards the ground state of mousepluripotency by strengthening the robustness of the transcriptional apparatus - Science Advances - July 19th, 2020
- COVID-19 Impact on Cell Therapy Industry 2020: Global Market Size, Share, Emerging Trends, Business Growth Applications, SWOT Analysis by Top Key... - July 17th, 2020
- Somatic Cells: Meaning, Characteristics, Types and Examples - July 15th, 2020
- Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners - BusinessGhana - July 10th, 2020
- Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners - Business Wire - July 10th, 2020
- Global Tooth Regeneration Market : Industry Analysis and Forecast (2020-2027)-by Type, Application, Population Demographics and Region. - Morning Tick - July 6th, 2020
- REGENERATIVE MEDICINE MARKET ALONG WITH COVID-19 IMPACT ANALYSIS AND CLINICAL OUTLOOK 2022 | STRYKER CORPORATION, ZIMMER BIOMET HOLDINGS INC.,... - July 2nd, 2020
- Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities - GlobeNewswire - June 25th, 2020
- Estrogen induces dynamic ER and RING1B recruitment to control gene and enhancer activities in luminal breast cancer - Science Advances - June 8th, 2020
- Participation of Somatic Stem Cells, Labeled by a Unique ... - June 5th, 2020
- COVID-19 Impact on Global Cell Therapy Industry 2020: Market Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report... - June 5th, 2020
- A caveolin binding motif in Na/K-ATPase is required for stem cell differentiation and organogenesis in mammals and C. elegans - Science Advances - June 1st, 2020
- Global Tooth Regeneration Market : Industry Analysis And Forecast (2020-2027) - Azizsalon News - May 14th, 2020
- Somatic Stem Cells - Methods and Protocols | Shree Ram ... - May 13th, 2020
- What is the Value of iPSC Technology in Cardiac... - The Doctor Weighs In - May 7th, 2020
- Induced Pluripotent Stem Cells Market Latest Trends and Analysis Future Growth Study by 2029 Cole Reports - Cole of Duty - May 4th, 2020
- Global Zinc Finger Nuclease Technology Market to Generate Lucrative Revenue Prospects for Manufacturers After the End of COVID-19 Crisis and Forecast... - May 4th, 2020
- Normal human uterus is colonised by clones with cancer-driving mutations that arise early in life, study finds - Cambridge Network - April 24th, 2020
- Global Tooth Regeneration Market: Industry Analysis and Forecast (2020-2027) - Publicist360 - April 17th, 2020
- Scientists 'Reset' The Age of Stem Cells From a Supercentenarian Who Lived to 114 - ScienceAlert - March 25th, 2020
- Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia - BioSpace - March 11th, 2020
- Mapping the structure and biological functions within mesenchymal bodies using microfluidics - Science Advances - March 4th, 2020
- Researchers ID Protein-Protein Interaction That Promotes Cancer Development - BioSpace - February 28th, 2020
- Dental Regenerative Market Size, Share 2020 Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by... - February 28th, 2020
- Global Gene Therapy Market to Cross Around USD 6892 Million By 2027 - Global Newspaper 24 - February 17th, 2020
- Induced Pluripotent Stem Cells Market Predicted to Witness Surge in the Near Future2018 2028 - TechNews.mobi - February 15th, 2020
- Global Gene Therapy Market Worth Reach USD 6892 Million By 2027 - TheInfobiz - February 12th, 2020
- New research shows what happens to your lung cells once you quit smoking - Daily Gaming Worlld - February 9th, 2020
- Global Gene Therapy Market to Cross USD 6892 Million By 2027 - TheInfobiz - February 6th, 2020
- Scientists finally find link between stress and grey hair - nation.co.ke - January 31st, 2020
- Global Gene Therapy Market is Growing to Reach 6892 Million By 2027 - Market Research News 24 - January 29th, 2020
- Going Gray Too Soon? Scientists Say It Really May Be Due to Stress - Genetic Engineering & Biotechnology News - January 25th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire - January 20th, 2020
- Duke researchers land $6M in federal grants to advance gene editing - WRAL Tech Wire - January 5th, 2020
- Stem Cells Market- What Are The Main Factors That Contributing Towards Industry Growth? - Industry Mirror - December 31st, 2019
- What a time to be alive: Reproductive breakthroughs of the 2010s that changed life as we know it - FOX 10 News Phoenix - December 29th, 2019
- Gene Therapy Market 2019-2027 / Trends, Growth, Opportunities And Top Key - Market Research Sheets - December 27th, 2019
- Cell Therapy Industry Applications 2019-Size by Type (Allogenic Therapies), by Technique (Stem Cell Therapy), Global Market Growth by Demand Analysis... - December 13th, 2019
- Stem Cell Therapies Market research Likely to Emerge over a Period of 2015-2025 - PharmiWeb.com - December 13th, 2019
- Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals - Proactive Investors USA & Canada - December 6th, 2019
- Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia - BioSpace - December 6th, 2019
- Stem Cell Therapy Industry 2019 Global Market Size, Trends, Revenue, Growth Prospects, Key Companies and Forecast by 2023 - Techi Labs - December 6th, 2019
- Brave new world? Why the public might be ready for gene-edited babies - Genetic Literacy Project - December 6th, 2019